TermSheet

Neuralink

Implantable brain-computer interfaces designed to restore autonomy for people with severe neurological impairments.

Private; venture-backed clinical-stage medical device companyFremont, California, United States

Cumulative raised across 3 rounds, totaling $1.18B.

Fundraising history.

Cumulative raised$1.18BJul 2021 to Jun 2025 · 3 rounds
Jul 2021Aug 2023Jun 2025
  1. Series C — $205M

    Jul 2021

    Neuralink raised a $205 million Series C led by Vy Capital.

    Led by Vy Capital · with Founders Fund, GV, DFJ Growth, Valor Equity Partners +2

    Source ↗
  2. Series D — $323M

    Aug 2023

    Neuralink’s Series D was reported as a Founders Fund-led tranche that increased from $280 million to $323 million.

    Led by Founders Fund

    Source ↗
  3. Series E — $650M

    Jun 2025

    Neuralink closed a $650 million Series E financing to expand patient access and develop new devices.

    Investors: ARK Invest, DFJ Growth, Founders Fund, G42 +7

    Source ↗

Implantable brain-computer interfaces designed to restore autonomy for people with severe neurological impairments.

Neuralink develops implantable brain-computer interface technology that records neural activity and translates intended movement or communication signals into control of external devices. The company’s PRIME study evaluates its N1 Implant, R1 Robot, and N1 User App in participants with paralysis, while its broader roadmap includes assistive applications for computer control, robotic arms, speech restoration, and vision-related research. Neuralink is privately held and venture-backed; its devices remain investigational and are not commercially available or FDA approved.

Company links